Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 3/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.63 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.63 |
| ▸ | POLG | P54098 | 2/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcitabine Triphosphate SCHEMBL15160598 | 1.00 | POLA1 (0.69) | POLA1PDE4DPDE3ASLC29A1POLG | |
| Gemcitabine Triphosphate SCHEMBL5598638 | 1.00 | POLA1 (0.69) | POLA1PDE4DPDE3ASLC29A1POLG | |
| Gemcitabine Triphosphate SCHEMBL21465271 | 1.00 | POLA1 (0.69) | POLA1PDE4DPDE3ASLC29A1POLG | |
| SCHEMBL369565 | 0.98 | POLA1 (0.71) | POLA1PDE4DPDE3ASLC29A1POLG | |
| SCHEMBL369566 | 0.98 | POLA1 (0.71) | POLA1PDE4DPDE3ASLC29A1POLG | |
| SCHEMBL25274623 | 0.98 | POLA1 (0.71) | POLA1PDE4DPDE3ASLC29A1POLG | |
| SCHEMBL10361430 | 0.93 | POLA1 (0.69) | POLA1PDE4DPDE3ASLC29A1POLG | |
| SCHEMBL10361380 | 0.92 | POLA1 (0.70) | POLA1PDE4DPDE3ASLC29A1POLG | |
| SCHEMBL4576331 | 0.92 | POLG (0.58) | POLA1PDE4DPDE3ASLC29A1POLG | |
| Psi-6130-Tp SCHEMBL12799368 | 0.91 | POLA1 (0.59) | POLA1PDE4DPDE3ASLC29A1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3359163-B1 | COMBINATION THERAPY | NuCana plc (GB) | 2023-12-20 | — | — | EP | claimed |
| US-20070025910-A1 | Anticancer therapy | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-02-01 | — | — | US | claimed |
| EP-4746876-A1 | UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER | Katholieke Universiteit Leuven (BE) | 2026-05-27 | — | — | EP | disclosed |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4724107-A2 | OPHTHALMIC FILMS | Fount Bio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260048152-A1 | GEMCITABINE INORGANIC-ORGANIC HYBRID NANOPARTICLES | KARLSRUHER INSTITUT FUER TECH KOERPERSCHAFT DES OEFFENTLICHEN RECHTS (DE) | 2026-02-19 | — | — | US | disclosed |
| US-20260028622-A1 | RNA NANOSTRUCTURES WITH BASE MODIFICATIONS FOR REDUCING INNATE IMMUNOGENICITY | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260009798-A1 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | ACRIVON THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-3076946-B1 | COMPOSITIONS COMPRISING ANTIOXIDANT, FLUID DISPENSERS, AND METHODS INVOLVING THE SAME | ALZET LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12492217-B2 | Reagents and their use for modular enantiodivergent synthesis of C—P bonds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| US-12448624-B2 | Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same | INTEROLIGO CORPORATION (KR) | 2025-10-21 | — | — | US | disclosed |
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-02 | — | — | US | disclosed |
| WO-2015081133-A2 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| EP-2217611-B1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8388966-B2 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| WO-2010085654-A1 | HEDGEHOG PATHWAY INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-07-29 | — | — | WO | disclosed |
| US-20090004200-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2009-01-01 | — | — | US | disclosed |
| EP-1085884-B1 | COMBINATION OF COMPOUNDS CONTAINING SELENIUM AND GEMCITABINE OR MITOMYCIN C | BIOSYN ARZNEIMITTEL GMBH (DE) | 2005-03-09 | — | — | EP | disclosed |
| US-20030091574-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | POLA1 49/4885PDE4D 537/4885PDE3A 1610/4885 |
| US-20260048152-A1 | GEMCITABINE INORGANIC-ORGANIC HYBRID NANOPARTICLES | GOT1, RNMT, GNAO1 | POLA1 102/4885PDE4D 1933/4885PDE3A 936/4885 |
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | RNMT, NUDT1, NTPCR | POLA1 146/4885PDE4D 1349/4885PDE3A 2368/4885 |
| US-20260009798-A1 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | CHEK1, CHEK2, CKS1B | POLA1 1067/4885PDE4D 4844/4885PDE3A 4807/4885 |
| US-20260028622-A1 | RNA NANOSTRUCTURES WITH BASE MODIFICATIONS FOR REDUCING INNATE IMMUNOGENICITY | NSUN3, TARBP1, TRDMT1 | POLA1 354/4885PDE4D 3867/4885PDE3A 4637/4885 |
| US-12492217-B2 | Reagents and their use for modular enantiodivergent synthesis of C—P bonds | PNKP, POLL, RNGTT | POLA1 138/4885PDE4D 752/4885PDE3A 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.